Study to Evaluate Immune Responses in Neurologically Normal Cancer Patients
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Cancer, Healthy Studies |
| Therapuetic Areas: | Oncology, Other |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/6/2018 |
| Start Date: | March 1998 |
| End Date: | December 2020 |
| Contact: | Mayu Frank, MS ANP |
| Email: | frankm@rockefeller.edu |
| Phone: | 212-327-7443 |
Tumor Immunity in Neurologically Normal Patients
The purpose of this study is to study whether immune cells capable of killing tumors that
express proteins associated with paraneoplastic neurologic syndrome (PNS) can be found in
small cell lung cancer and ovarian cancer patients. The presence of these cells may play a
role in tumor immunity in these patients. The protocol involves neurological examinations and
collection of blood.
express proteins associated with paraneoplastic neurologic syndrome (PNS) can be found in
small cell lung cancer and ovarian cancer patients. The presence of these cells may play a
role in tumor immunity in these patients. The protocol involves neurological examinations and
collection of blood.
See brief description
Inclusion Criteria:
1. Males and females ages 25 -75
2. If leukapheresis:
Hepatitis B surface antigen negative if tested* Hepatitis C antibody negative if
tested* HIV antibody negative if tested* Venereal disease reaction level (VDRL)
negative if tested* No known IV drug users Hemoglobin > 8.5 White blood cell count >
3,800 Platelets > 120,000 International normalized ratio (INR) < 2 (verified only if
clinically indicated)
3. If large blood draw (1/2 to 1 unit) in lieu of leukapheresis:
Hepatitis B surface antigen negative if tested* Hepatitis C antibody negative if tested*
HIV antibody negative if tested* VDRL negative if tested* No known IV drug users HgB > 10.0
WBC > 3,800 Platelets > 120,000 INR < 2 (verified only if clinically indicated)
Exclusion Criteria:
No known neurologic disease 2. No known central nervous system (CNS) metastasis on clinical
exam 3. No chemotherapy within 1 month 4. No New York Heart Association class III/IV status
5. No pulmonary disease which limits daily activities 6. No anticoagulation therapy
We found this trial at
1
site
New York, New York 10021
Principal Investigator: Robert Darnell, MD, PHD
Phone: 212-327-7443
Click here to add this to my saved trials
